Goldman Sachs Group Inc Aquestive Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $555 Billion
- Q1 2024
A detailed history of Goldman Sachs Group Inc transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 526,422 shares of AQST stock, worth $1.52 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
526,422
Previous 30,499
1626.03%
Holding current value
$1.52 Million
Previous $61,000
3575.41%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding AQST
# of Institutions
105Shares Held
42.1MCall Options Held
463KPut Options Held
431K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$28.3 Million100.0% of portfolio
-
Vr Adviser, LLC New York, NY5.56MShares$16 Million2.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.24MShares$9.34 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA2.22MShares$6.39 Million0.0% of portfolio
-
Laurion Capital Management LP New York, NY1.55MShares$4.45 Million0.06% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $154M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...